製品名:Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate

IUPAC Name:ethyl 4-bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate

CAS番号:5775-89-3
分子式:C8H11BrN2O2
純度:95%
カタログ番号:CM313111
分子量:247.09

包装単位 有効在庫 価格(USD) 数量
CM313111-5g in stock ƛŵǶ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:5775-89-3
分子式:C8H11BrN2O2
融点:-
SMILESコード:O=C(C1=C(Br)C(C)=NN1C)OCC
密度:
カタログ番号:CM313111
分子量:247.09
沸点:
MDL番号:MFCD02253803
保管方法:

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.

Column Infos

Lorlatinib
Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.

Related Products